Journal of obstetrics and gynaecology Canada最新文献

{"title":"Expanding First-Trimester Preterm Preeclampsia Screening With Placental Growth Factor Testing","authors":"Nan Okun MD,&nbsp;Jo-Ann Johnson MD,&nbsp;Stefania Ronzoni MD,&nbsp;Tianhua Huang MBBS, PhD,&nbsp;Emmanuel Bujold MD, MSc","doi":"10.1016/j.jogc.2026.103394","DOIUrl":"10.1016/j.jogc.2026.103394","url":null,"abstract":"<div><div>Preterm preeclampsia, which affects 0.5%–1% of pregnancies, can be prevented with aspirin initiated before 16 weeks. However, its effectiveness is highly dependent on adherence. Screening for preterm preeclampsia based on clinical factors alone is associated with a high number needed to treat (&gt;100) and poor treatment adherence. Conversely, a review of current evidence shows that a multiple marker algorithm including placental growth factor and standardized blood pressure measurement is associated with lower number needed to treat (&lt;30) and improved treatment adherence and enables personalized follow-up care. Our review identifies that offering this combined approach to all pregnant persons could provide a more comprehensive first-trimester risk assessment for preeclampsia.</div></div>","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":"48 7","pages":"Article 103394"},"PeriodicalIF":2.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147937209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comparison of Preeclampsia Screening Using Clinical Risk Factors and the Fetal Medicine Foundation Algorithm","authors":"Paul Guerby MD, PhD,&nbsp;Louise Ghesquiere MD, PhD,&nbsp;Francois Audibert MD, MSc,&nbsp;Nan Okun MD,&nbsp;Jo-Ann Jonhson MD,&nbsp;Jean-Claude Forest MD, PhD,&nbsp;Yves Giguère MD, PhD,&nbsp;Emmanuel Bujold MD, MSc","doi":"10.1016/j.jogc.2026.103391","DOIUrl":"10.1016/j.jogc.2026.103391","url":null,"abstract":"<div><div>Aspirin can prevent most preterm preeclampsia in high-risk women. The risk can be estimated either by considering clinical factors or by using the Fetal Medicine Foundation (FMF) algorithm, which considers placental growth factor with blood pressure and other markers. Among nulliparous women, a low FMF risk is associated with low incidences of preeclampsia (&lt;2.5%) and preterm preeclampsia (&lt;0.5%), and a high FMF risk is associated with high incidences of preeclampsia (&gt;6%) and preterm preeclampsia (&gt;1.5%; <em>P</em> &lt; 0.001), regardless of clinical risk factors. Where available, the FMF algorithm including placental growth factor should be the only tool used for preeclampsia screening.</div></div>","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":"48 7","pages":"Article 103391"},"PeriodicalIF":2.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147871276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Placental Growth Factor and Uterine-Artery Doppler for Prediction of Preeclampsia, Fetal Growth Restriction and Early Preterm Birth","authors":"Ernesto A. Figueiro-Filho MD, PhD,&nbsp;Adrielle P. Souza Lira BSN, RN,&nbsp;Genevieve M. Dietrich BSc, MEng,&nbsp;YiChen Li BMSc,&nbsp;John Matelski,&nbsp;Eman Ramadan MD,&nbsp;Adewumi Adanlawo MD,&nbsp;Juan-Nicolás Peña-Sánchez MD, PhD","doi":"10.1016/j.jogc.2026.103389","DOIUrl":"10.1016/j.jogc.2026.103389","url":null,"abstract":"<div><h3>Objectives</h3><div>To assess whether placental growth factor (PlGF) and uterine artery (UtA) Doppler measured at 20–28 weeks can predict preeclampsia (PE), fetal growth restriction or small for gestational age (FGR/SGA), and preterm birth before 34 weeks (PTB &lt; 34 w).</div></div><div><h3>Methods</h3><div>From December 2021 to January 2025, PlGF testing and UtA Doppler were offered prospectively between 20 and 28 weeks in a high-risk obstetric population. Low PlGF was defined as &lt;5th percentile for gestational age. Abnormal UtA was defined as a mean pulsatility index &gt;95th percentile or diastolic notching. PE, FGR/SGA, and PTB were recorded. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value were calculated.</div></div><div><h3>Results</h3><div>Of 223 participants enrolled, 74 had both PlGF and UtA measurements. PE occurred in 14/74 (18.9%), FGR/SGA in 22/74 (29.7%), and PTB &lt; 34 weeks in 19/74 (25.6%). PlGF alone detected PE with 71% sensitivity and 37% PPV, FGR/SGA with 68% sensitivity and 60% PPV, and PTB &lt; 34 weeks with 68% sensitivity and 57% PPV. UtA alone had low sensitivity (45%–53%) and PPV (28%–53%). Low PlGF and/or abnormal UtA maximized sensitivity, 86% for PE, 68% for FGR/SGA, and 74% for PTB &lt; 34 weeks, but reduced specificity (57%–60%). Low PlGF plus abnormal UtA improved PPV for FGR/SGA (77%) and PTB &lt; 34 weeks (82%) but had limited sensitivity (36%–47%).</div></div><div><h3>Conclusions</h3><div>PlGF measurement alone showed superior predictive power for PE, FGR/SGA, and PTB &lt; 34 weeks. UtA Doppler combined with PlGF enhanced sensitivity or raised PPV. Abnormal UtA without low PlGF provided minimal incremental detection.</div></div>","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":"48 7","pages":"Article 103389"},"PeriodicalIF":2.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147871244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioethical Considerations of Diagnostic Placental Growth Factor Testing in Canada","authors":"Rebecca L. Zur MD, MHSc,&nbsp;Naila Ramji MDCM, MSc","doi":"10.1016/j.jogc.2026.103392","DOIUrl":"10.1016/j.jogc.2026.103392","url":null,"abstract":"<div><div>There is strong clinical evidence to support the use of diagnostic placental growth factor testing in the second and third trimesters for early preeclampsia detection and growing evidence to support its use in the prediction/management of fetal growth restriction. However, as centres across the country move to adopt a national placental growth factor testing implementation strategy, there are important bioethical issues to consider. These include individual considerations relating to the bioethical principles of autonomy, beneficence, non-maleficence, and justice, as well as moral considerations involved in health technology assessment and epistemic bioethical concerns at the systems level. These relate to resource allocation, trade-offs, and cost-effectiveness, as well as risk management and practical considerations around informed consent, professional liability, and the physician–patient relationship.</div></div>","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":"48 7","pages":"Article 103392"},"PeriodicalIF":2.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147871245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Considerations for Implementing Placental Growth Factor–Based Testing in Urban and Rural Regions in Canada","authors":"Jessica Liauw MD, MHSc,&nbsp;Jennifer A. Hutcheon PhD,&nbsp;Elise Lavoie Lebel MD, MSc,&nbsp;Karen C. Tran MD, MHSc","doi":"10.1016/j.jogc.2026.103393","DOIUrl":"10.1016/j.jogc.2026.103393","url":null,"abstract":"<div><div>Placental growth factor (PlGF)–based testing is a promising strategy to improve risk stratification of pregnant persons presenting with hypertensive disorders of pregnancy in Canada. However, implementation of PlGF-based testing may have different implications in urban versus rural regions. In this review, we summarize key evidence on PlGF-based testing for persons with suspected or confirmed preeclampsia and describe the differences in how it may translate to urban and rural practice settings. We use clinical vignettes to illustrate practical impacts and challenges of using PlGF-based testing for a typical clinical scenario presenting to Canadian centres.</div></div>","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":"48 7","pages":"Article 103393"},"PeriodicalIF":2.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147937156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rethinking Preeclampsia: How Placental Growth Factor Is Transforming Diagnosis and Management","authors":"John W. Snelgrove MD, MSc","doi":"10.1016/j.jogc.2026.103396","DOIUrl":"10.1016/j.jogc.2026.103396","url":null,"abstract":"<div><div>Preeclampsia is a severe pregnancy complication affecting pregnant people, their babies, and families. It remains a leading global cause of maternal and fetal morbidity and mortality. Our understanding of this disease continues to evolve, with opportunities for improved preeclampsia prediction, diagnosis, and management. This review outlines how placental growth factor could help clinicians better predict, diagnose, and ultimately manage preeclampsia and its complications. The material was originally presented at the Cannell Lecture in Toronto on November 29, 2024. The Cannell Lecture is hosted annually by the Society of Obstetricians &amp; Gynaecologists of Canada and the University of Toronto in honour of Dr. Doug Cannell, who was Chair of the Department of Obstetrics &amp; Gynaecology from 1950 to 1965.</div></div>","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":"48 7","pages":"Article 103396"},"PeriodicalIF":2.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147978412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lignes directrices de pratique clinique n° 468 : Prise en charge clinique de l'endométriose","authors":"Paul J. Yong MD,&nbsp;Catherine Allaire MD,&nbsp;Mohamed Bedaiwy MD,&nbsp;Olga Bougie MD,&nbsp;Sari Kives MD,&nbsp;Sarah Maheux-Lacroix MD,&nbsp;Ally Murji MD,&nbsp;Sukhbir S. Singh MD","doi":"10.1016/j.jogc.2026.103383","DOIUrl":"10.1016/j.jogc.2026.103383","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objectif&lt;/h3&gt;&lt;div&gt;Recommander aux professionnels(les) de la santé une approche fondée sur des données probantes pour la prise en charge de l'endométriose et de ses symptômes associés.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Population cible&lt;/h3&gt;&lt;div&gt;Les femmes et les personnes de tous genres touchés par l'endométriose.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Avantages, inconvénients et coûts&lt;/h3&gt;&lt;div&gt;Une prise en charge rapide et efficace de l'endométriose peut réduire la douleur, améliorer la fertilité et la qualité de vie, et optimiser les résultats de santé à long terme. Une intervention précoce peut également contribuer à atténuer les répercussions financières et les pressions exercées sur le système de santé associées à un retard de diagnostic et de traitement.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Données probantes&lt;/h3&gt;&lt;div&gt;La littérature publiée a été recueillie à partir de recherches effectuées dans PubMed, Ovid, Medline, Embase, Scopus et la Cochrane Library entre août 2010 et décembre 2025, à l’aide de termes MeSH et de mots-clés pertinents. Les résultats ont été limités aux revues systématiques, aux méta-analyses, aux essais contrôlés randomisés/essais cliniques contrôlés, aux études observationnelles et aux lignes directrices de pratique clinique. Les résultats ont été limités aux documents en anglais ou en français. Les données probantes ont été complétées par les références issues de la ligne directrice n° 244 de la Société des obstétriciens et gynécologues du Canada de 2010.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthodes de validation&lt;/h3&gt;&lt;div&gt;Les auteurs ont évalué la qualité des données probantes et la force des recommandations à l’aide de l’approche GRADE (Grading of Recommendations Assessment, Development and Evaluation). Voir l’annexe A en ligne (&lt;span&gt;&lt;span&gt;tableaux A1&lt;/span&gt;&lt;/span&gt; pour les définitions et &lt;span&gt;&lt;span&gt;A2&lt;/span&gt;&lt;/span&gt; pour les interprétations des recommandations fortes et conditionnelles).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Public visé&lt;/h3&gt;&lt;div&gt;Les professionnels(les) de la santé impliqués(es) dans la prise en charge des personnes atteintes d'endométriose.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Résumé sur les réseaux sociaux&lt;/h3&gt;&lt;div&gt;Le dépistage précoce et la prise en charge de l'endométriose peuvent améliorer considérablement les résultats cliniques, réduire les coûts de santé à long terme et améliorer la qualité de vie des patientes.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Déclarations Sommaires&lt;/h3&gt;&lt;div&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;1.&lt;/span&gt;&lt;span&gt;&lt;div&gt;L'endométriose est une maladie chronique qui nécessite une approche centrée sur la patiente et une prise en charge à long terme individualisée; celle-ci peut être multidisciplinaire et inclure des interventions médicales, chirurgicales, de traitement de la douleur et/ou liées à la fertilité. (élevée)&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;2.&lt;/span&gt;&lt;span&gt;&lt;div&gt;Le traitement médical peut constituer une option efficace pour la prise en charge des symptômes douloureux de l'endométriose. Cependant, chacune des différentes options présente des avantages et des effets secondaires qui lui est propre (élevée).&lt;/d","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":"48 6","pages":"Article 103383"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147794595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulating Women’s Health Products in Canada","authors":"Redha Benyoucef BSc,&nbsp;Isabelle Rousse MSc,&nbsp;Maxime Sasseville MSc, PhD,&nbsp;Melissa Hunt MSc","doi":"10.1016/j.jogc.2026.103375","DOIUrl":"10.1016/j.jogc.2026.103375","url":null,"abstract":"","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":"48 6","pages":"Article 103375"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147864884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guideline No. 468: Clinical Management of Endometriosis","authors":"Paul J. Yong MD,&nbsp;Catherine Allaire MD,&nbsp;Mohamed Bedaiwy MD,&nbsp;Olga Bougie MD,&nbsp;Sari Kives MD,&nbsp;Sarah Maheux-Lacroix MD,&nbsp;Ally Murji MD,&nbsp;Sukhbir S. Singh MD","doi":"10.1016/j.jogc.2026.103382","DOIUrl":"10.1016/j.jogc.2026.103382","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To provide health care professionals with an evidence-based approach to the management of endometriosis and its associated symptoms.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Target Population&lt;/h3&gt;&lt;div&gt;Women and gender-diverse individuals affected by endometriosis.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Benefits, Harms, and Costs&lt;/h3&gt;&lt;div&gt;Timely and effective management of endometriosis has the potential to reduce pain, improve fertility and quality of life, and enhance long-term health outcomes. Early intervention may also help mitigate the financial and health system burdens associated with delayed diagnosis and treatment.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Evidence&lt;/h3&gt;&lt;div&gt;Published literature was retrieved through searches of PubMed, Ovid, Medline, Embase, Scopus, and the Cochrane Library from August 2010 through December 2025, using relevant MeSH heading and keywords. Results were restricted to systematic reviews, meta-analyses, randomized controlled trials/controlled clinical trials, observational studies, and clinical practice guidelines. Results were limited to English or French language materials. Evidence was supplemented with references from the 2010 Society of Obstetricians and Gynaecologists of Canada guideline No. 244.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Validation Methods&lt;/h3&gt;&lt;div&gt;The authors rated the quality of evidence and strength of recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. See online &lt;span&gt;&lt;span&gt;Appendix A&lt;/span&gt;&lt;/span&gt; (&lt;span&gt;&lt;span&gt;Tables A1&lt;/span&gt;&lt;/span&gt; for definitions and &lt;span&gt;&lt;span&gt;A2&lt;/span&gt;&lt;/span&gt; for interpretations of strong and conditional recommendations).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Intended Audience&lt;/h3&gt;&lt;div&gt;Health care providers involved in the care of individuals with endometriosis.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Social Media Abstract&lt;/h3&gt;&lt;div&gt;Early identification and management of endometriosis can significantly improve patient outcomes, reduce long-term health care costs and improve their quality of life.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;SUMMARY STATEMENTS&lt;/h3&gt;&lt;div&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;1.&lt;/span&gt;&lt;span&gt;&lt;div&gt;Endometriosis is a chronic condition that requires a patient-centred and individualized approach to long term management which may be multidisciplinary and include medical, surgical, pain and/or fertility interventions. (high)&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;2.&lt;/span&gt;&lt;span&gt;&lt;div&gt;Medical treatment can be an effective option for managing endometriosis pain symptoms, however, each of the various options has unique advantages and side-effects (high).&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;3.&lt;/span&gt;&lt;span&gt;&lt;div&gt;Post operative hormonal therapy may aid in reducing disease and/or symptom recurrence after effective surgical management. (high)&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;4.&lt;/span&gt;&lt;span&gt;&lt;div&gt;In adolescent patients with presumed or diagnosed endometriosis, hormonal therapy is an effective option for managing symptoms, but careful consideration of the impact on bone health is essential. (high)&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;5.&lt;/span&gt;&lt;span&gt;&lt;div&gt;The surgical ap","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":"48 6","pages":"Article 103382"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147794628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Market Access Challenges for Innovative Medications in Women’s Health in Canada: Overview of the Past 20 Years","authors":"Maggie Dong PhD,&nbsp;Avril Gouault Laliberté MSc,&nbsp;Dany Hallé MSc,&nbsp;Édith Sirard MSc, MBA,&nbsp;Carla Létourneau BCom,&nbsp;Catherine Beauchemin PhD","doi":"10.1016/j.jogc.2026.103341","DOIUrl":"10.1016/j.jogc.2026.103341","url":null,"abstract":"<div><div>In an era of growing awareness of barriers to women’s health, this study aimed to generate quantifiable evidence on the challenges associated with introducing innovative medication for women’s health in Canada. A targeted literature search was conducted to assess regulatory and reimbursement status of women’s health medications over 20 years. Of 45 medications approved in the United States, only 53% were approved in Canada. From approval to patient access, women’s health medications take 1 year longer than new drugs in general. It is critical for stakeholders to remove barriers and ensure that Canadian women have timely access to innovative medications.</div></div>","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":"48 6","pages":"Article 103341"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147719341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}